loading
Bausch Health Companies Inc stock is currently priced at $6.24, with a 24-hour trading volume of 961.52K. It has seen a +1.13% increased in the last 24 hours and a -12.36% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $6.24 pivot point. If it approaches the $6.31 resistance level, significant changes may occur.
Previous Close:
$6.17
Open:
$6.11
24h Volume:
961.52K
Market Cap:
$2.29B
Revenue:
$8.76B
Net Income/Loss:
$-592.00M
P/E Ratio:
-2.3636
EPS:
-2.64
Net Cash Flow:
$760.00M
1W Performance:
-0.48%
1M Performance:
-12.36%
6M Performance:
-16.47%
1Y Performance:
-14.75%
1D Range:
Value
$6.05
$6.25
52W Range:
Value
$6.05
$11.46

Bausch Health Companies Inc Stock (BHC) Company Profile

Name
Name
Bausch Health Companies Inc
Name
Phone
514-744-6792
Name
Address
2150 St. Elzéar Boulevard West, Laval, QC
Name
Employee
20,700
Name
Twitter
Name
Next Earnings Date
2024-05-14
Name
Latest SEC Filings
Name
BHC's Discussions on Twitter

Bausch Health Companies Inc Stock (BHC) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-20-23 Upgrade Jefferies Hold → Buy
Jun-16-23 Downgrade TD Cowen Outperform → Market Perform
Jul-29-22 Downgrade RBC Capital Mkts Outperform → Sector Perform
Jul-29-22 Downgrade Truist Buy → Hold
Jul-28-22 Downgrade JP Morgan Overweight → Neutral
Jun-13-22 Resumed JP Morgan Overweight
Mar-24-21 Downgrade BofA Securities Neutral → Underperform
Feb-17-21 Upgrade RBC Capital Mkts Sector Perform → Outperform
Jan-22-21 Downgrade Piper Sandler Overweight → Neutral
Sep-17-20 Upgrade BofA Securities Underperform → Neutral
Aug-24-20 Reiterated H.C. Wainwright Buy
Jun-17-20 Reiterated H.C. Wainwright Buy
Apr-24-20 Initiated Citigroup Buy
Apr-02-20 Downgrade Morgan Stanley Overweight → Equal-Weight
Jan-29-20 Downgrade Wolfe Research Outperform → Peer Perform
Jan-22-20 Upgrade Wells Fargo Underweight → Equal Weight
Dec-12-19 Upgrade JP Morgan Neutral → Overweight
Dec-02-19 Initiated Goldman Neutral
Oct-25-19 Initiated Cowen Outperform
Sep-12-19 Initiated Guggenheim Buy
Aug-15-19 Upgrade TD Securities Hold → Buy
Jul-19-19 Initiated Wolfe Research Outperform
Jun-11-19 Resumed Barclays Overweight
May-13-19 Upgrade JP Morgan Underweight → Neutral
Mar-20-19 Initiated SunTrust Buy
Jan-02-19 Upgrade Piper Jaffray Neutral → Overweight
Nov-05-18 Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-13-18 Upgrade Piper Jaffray Underweight → Neutral
View All

Bausch Health Companies Inc Stock (BHC) Financials Data

Bausch Health Companies Inc (BHC) Revenue 2024

BHC reported a revenue (TTM) of $8.76 billion for the quarter ending December 31, 2023, a +7.79% rise year-over-year.
loading

Bausch Health Companies Inc (BHC) Net Income 2024

BHC net income (TTM) was -$592.00 million for the quarter ending December 31, 2023, a -163.11% decrease year-over-year.
loading

Bausch Health Companies Inc (BHC) Cash Flow 2024

BHC recorded a free cash flow (TTM) of $760.00 million for the quarter ending December 31, 2023, a +176.31% increase year-over-year.
loading

Bausch Health Companies Inc (BHC) Earnings per Share 2024

BHC earnings per share (TTM) was -$1.62 for the quarter ending December 31, 2023, a -161.29% decline year-over-year.
loading
Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal. The company also develops and markets products that treat gastrointestinal and hepatologic conditions comprising hepatic encephalopathy, irritable bowel syndrome with diarrhea, traveler's diarrhea, opioid-induced constipation, ulcerative colitis, and others. In addition, it offers eye health products, such as contact lens; products that treat various eye conditions, including glaucoma, eye allergies, conjunctivitis, dry eye, and retinal diseases; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for the treatment of cataracts, and vitreous and retinal eye conditions. Further, the company provides products in the therapeutic areas of epilepsy, migraines, depression, chronic pain, and rare diseases such, as huntington's disease; and oral health products for adult periodontitis and mouth dryness, as well as teeth-whitening. Additionally, it offers eye drops; skin care products, including moisturizers; and eye vitamins and mineral supplements, as well as neurology products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. was founded in 1983 and is headquartered in Laval, Canada.
$67.89
price down icon 0.75%
$18.07
price down icon 0.22%
$55.51
price down icon 0.87%
drug_manufacturers_specialty_generic RDY
$72.24
price down icon 0.51%
$10.35
price down icon 2.63%
$135.01
price down icon 0.84%
Cap:     |  Volume (24h):